Nan Li
- Oncology top 2%
- Peptidase Inhibition and Analysis 25
- Cancer Immunotherapy and Biomarkers 21
-
- Medical Imaging Techniques and Applications 32
- Radiopharmaceutical Chemistry and Applications 26
- Radiomics and Machine Learning in Medical Imaging 23
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms 12
- Immunology top 5%
-
- Lung Cancer Diagnosis and Treatment 15
-
- Neuroendocrine Tumor Research Advances 10
- Journals
- Journal of Clinical Investigation (2 papers)Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Nan Li
135 papers receiving 2.6k citations
Peers
Comparison fields: 5 of 124
- Oncology 1.0k
- Radiology, Nuclear Medicine and Imaging 805
- Cancer Research 495
- Immunology 488
- Pulmonary and Respiratory Medicine 614
Countries citing papers authored by Nan Li
This map shows the geographic impact of Nan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Li more than expected).
Fields of papers citing papers by Nan Li
This network shows the impact of papers produced by Nan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Li. The network helps show where Nan Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 1 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 6 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 8 | |
| 10 | 2023 | 2 | |
| 11 | 2023 | 11 | |
| 12 | 2023 | 56 | |
| 13 | 2022 | 1 | |
| 14 | 2022 | 48 | |
| 15 | 2022 | 3 | |
| 16 | 2021 | 4 | |
| 17 | 2021 | 18 | |
| 18 | 2016 | 1 | |
| 19 | 2015 | 2 | |
| 20 | Prognostic role of thymidylate synthase expression in gastric cancer:A meta-analysis | 2014 | 1 |
About Nan Li
Nan Li is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Cancer Research, having authored 152 papers that have together received 2.6k indexed citations. Recurring topics across this work include Medical Imaging Techniques and Applications (32 papers), Radiopharmaceutical Chemistry and Applications (26 papers), Peptidase Inhibition and Analysis (25 papers), Radiomics and Machine Learning in Medical Imaging (23 papers), Cancer Immunotherapy and Biomarkers (21 papers), Lung Cancer Diagnosis and Treatment (15 papers), Protease and Inhibitor Mechanisms (12 papers) and Neuroendocrine Tumor Research Advances (10 papers). The work is most often cited by research in Oncology (1.0k citations), Radiology, Nuclear Medicine and Imaging (805 citations) and Cancer Research (495 citations). Nan Li has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Hua Zhu, Zhi Yang, Amrish Sharma, Shinya Neri, Wen Jiang, Yifan Wang, Weiye Deng, Steven H. Lin, Teli Liu and Xiaoxia Xu. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.